Douglas W. Loe, analyst with Leede Jones Gable, has noted Revive Therapeutics (Revive Therapeutics S... Read More
Between 2013 and 2019, more than $115-billion in annual pharma sales will lose their patent protecti... Read More
Rett Syndrome breakthrough? Another play in Revive Therapeutics (Revive Therapeutics Stock Quote, Ch... Read More
Revive Therapeutics (TSXV:RVV) today announced that it has requested a pre-investigational New Drug ... Read More
Revive Therapeutics (TSXV:RVV) today announced results from a Phase 2a proof-of-concept study it cal... Read More